Metastatic paraganglioma and treatment with sunitinib: A case report

Tumori

Volumn 96, Issue 6, 2010, Pages 1022-1027

  Cirillo, Fernando ^a,b  

^a CREMONA HOSPITAL   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Neuroendocrine tumors; Paraganglioma; Side effects; Somatostatin analogs; Sunitinib; Targeted therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CHROMOGRANIN A; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; LEVOTHYROXINE; NAVELBINE; OCTREOTIDE; SOMATOSTATIN; SUNITINIB; THALIDOMIDE; VINCRISTINE;

ADULT; ANAMNESIS; ARTICLE; BONE METASTASIS; CANDIDIASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEMATURIA; HERPES SIMPLEX; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PARAGANGLIOMA; PARAPLEGIA; PROTEIN BLOOD LEVEL; RADIATION DOSE; TUMOR VOLUME;

EID: 79551481350     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/548.6526     Document Type: Article

References (36)

1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 9: 327-337, 2003.
2. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2: 471-478, 2003.
3. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK: SU 11248 inhibits tumor growth and CSF-1R-dependent osteolysis in a experimental breast cancer bone metastasis model. Clin Exp Metastasis, 20: 757-766, 2003.
4. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 101: 3597-3605, 2003.
5. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 24: 25-35, 2006.
6. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs C: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 26: 3403-3410, 2006.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92: 205-216, 2000.
8. Neumann HPH, Hoegerle S, Manz T, Brenner K, Iliopoulos O: How many pathways to pheochromocytomas? Semin Nephrol, 22: 88-99, 2002.
9. Fonseca V, Bouloux PM: Phaeochromocytoma and paraganglioma. Baillières Clin Endocrinol Metab, 7: 509-550, 1993.
10. Kebebew E, Duh QY: Benign and malignant pheochromocytoma: diagnosis, treatment and follow-up. Surg Oncol Clin N Am, 7: 765-789, 1998.
11. Bravo EL: Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocr Rev, 15: 356-368, 1994.
12. Cohen CD, Dent DM: Phaeochromocytoma and acute cardiovascular death (with special reference tomyocardial infarction). Postgrad Med, 60: 111-115, 1984.
13. Thomas JE, Rooke ED, Kvale WF: The neurologist's experience with pheochromocytoma: a review of 100 cases. JAMA, 197: 754-758, 1966.
14. Grossman AB, Kaltsas G: Adrenal medulla and pathology. In: Comprehensive clinical endocrinology, Besser GM, Thorner MO (eds), pp 223-237, 3rd ed, Elsevier Science, Philadelphia, 2002.
15. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T:Treatment of malignant pheochromocytoma/ paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer, 113: 2020-2028, 2008.
16. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Mazikansky A, Vincitore M, Michelini A, Fuchs CS: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol, 24: 401-406, 2006.
17. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res, 50: 5969-5977, 1990.
18. Oberg K, Kvols L, Caplin M: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol, 15: 966-973, 2004.
19. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer, 72: 244-248, 1993.
20. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Barth P, Wied M, Mayer C, Aminossadati B: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol, 27:15s (suppl; abstr 4508), 2009.
21. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB: Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res, 41: 697-702, 2009.
22. Turner HE, Harris AL, Melmed S, Wass JA: Angiogenesis in endocrine tumors. Endocr Rev, 24: 600-632, 2003.
23. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol, 34: 18-27, 2003.
24. Motzer RJ, Dror Michaelson M, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, De-Primo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI: Activity of SU11248, a multitargeted inhibitor or vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24: 16-24, 2006.
25. Négrier S, Ravaud A: Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer, 5: 12-19, 2007.
26. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D: A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol, 61: 515-524, 2008.
27. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 99: 81-83, 2007.
28. Rosen LS: Angiogenesis inhibition in solid tumors. Cancer J, 7: S120-128, 2001.
29. Ollivier L: International criteria for tumour assessment. Cancer Imaging, 1: 32-34, 2000.
30. Choi H: Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep, 7: 307-311, 2005.
31. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs, 10: 239-253, 1992.
32. Julka PK, Doval DC, Gupta S, Rath GK: Response assessment in solid tumours: a comparison of WHO, SWOG and Recist guidelines. Br J Radiol, 81: 444-449, 2008.
33. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer, 35: 1773-1782, 1999.
34. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori, 95: 382-384, 2009.
35. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol, 183: 1619-1628, 2004.
36. th World Congress on Gastrointestinal Cancer, 24-27 June, 2009, Barcelona, Spain: abstr O-0013, 2009.